



# SNO Digest

Weekly news from  
the Society for Neuro-Oncology

## Upcoming Webinars - Register Now



### **Barriers and Solutions to Equitable Access for Brain Tumor Survivors** **Wednesday, December 13, 2023, 12:00 - 1:30 PM ET**

On behalf of the Chairs of the Women and Diversity Committee and the Community Neuro Oncology Committee of the Society for Neuro-Oncology, this webinar will focus on solutions to the barriers and disparities in access to specialized care for survivors of brain cancer.

#### **Learning Objectives**

- To discuss the patient and caregiver experience regarding barriers and disparities in longitudinal access to specialized care for survivors of brain cancer.
- To review models of care, and barriers and disparities to equitable access to care, in cancer survivorship.
- To review experience and data regarding barriers to access to specialized oncocardiology care in cancer survivorship.

For full details and complimentary registration, [click here](#).

### **Adult Fellowship Match Educational Webinar** **Applying for a Neuro-Oncology Fellowship: What You Need to Know** **Thursday, December 14, 2023, 7:00 PM ET**

On behalf of the Chairs of the Adult Fellowship Match Committee of the Society for Neuro-Oncology, we are excited to announce an educational opportunity for residents applying to a Neuro-Oncology Adult Fellowship Match program.

#### **Learning Objectives**

- To provide practical education for residents applying to a Neuro-Oncology Adult Fellowship program regarding required timelines and expectations.
- To improve communication with residents by offering an opportunity to ask questions related to the application process to Fellowship Program Directors and Fellows who have gone through the process.

- To expand the outreach of this educational recording by creating an enduring material to post on the SNO Neuro-Oncology Academy to allow for future access for residents.

For full details and to register, [click here](#).

**The PROSPECT Study Is Enrolling at 43 Study Centers Across the US**

For eligible patients with newly diagnosed or relapsed/refractory PCNSL

**Learn More About Enrolling Potentially Eligible Patients ▶**

PCNSL=Primary Central Nervous System Lymphoma.

**ONO ONO PHARMA USA, INC.**

COPYRIGHT © 2023 ONO PHARMA USA, INC. ALL RIGHTS RESERVED. 07/23

## Call for Applications for the SNO Future Leaders Development Program

**SNO**  
Society for NeuroOncology

**SNO FUTURE LEADERS DEVELOPMENT PROGRAM**

The SNO Future Leaders Development Program seeks to cultivate the careers and train young physician-scientists to become future leaders in the field of neuro-oncology. This new program from SNO was developed to train young investigators to become leaders in brain tumor research, advance in their own academic departments and to lay the groundwork for leadership in the Society. Through mentorship and the application of a formalized training curriculum, this annual program will provide young investigators with practical skills and resources to allow them to excel in the field of neuro-oncology. [Apply Here!](#)

**Invaxx**

**NOW ENROLLING** – Phase 2b study of IGV-001 in patients with newly diagnosed glioblastoma ([NCT04485949](#))

**LEARN MORE**

## Neuro-Oncology: The Podcast

**Neuro-Oncology**

**The PODCAST**

**3D tumor volume assessment in PCNSL**

Dr. Rachna Malani interviews Dr. Florian Scherer about his and his team's recent manuscript entitled: "Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas", published online in Neuro-Oncology in Sep 2023. [Listen to the podcast.](#)

**CHIMERIX**

Conducting Phase 3 ACTION Study of **ONC201 (dordaviprone)** in H3 K27M-mutant Glioma | [NCT05580562](#)

**Learn More**

## From The Journals



## From *Neuro-Oncology* Pediatric low-grade glioma: State-of-the-art and ongoing challenges

The most common childhood central nervous system (CNS) tumor is pediatric low-grade glioma (pLGG), representing 30%–40% of all CNS tumors in children. Although there is high associated morbidity, tumor-related mortality is relatively rare. pLGG is now conceptualized as a chronic disease, underscoring the importance of functional outcomes and quality-of-life measures. A wealth of data has emerged about these tumors, including a better understanding of their natural history and their molecular drivers, paving the way for the use of targeted inhibitors. While these treatments have heralded tremendous promise, challenges remain about how to best optimize their use, and the long-term toxicities associated with these inhibitors remain unknown. The International Pediatric Low-Grade Glioma Coalition (iPLGGc) is a global group of physicians and scientists with expertise in pLGG focused on addressing key pLGG issues. Here, the iPLGGc provides an overview of the current state-of-the-art in pLGG, including epidemiology, histology, molecular landscape, treatment paradigms, survival outcomes, functional outcomes, imaging response, and ongoing challenges. This paper also serves as an introduction to 3 other pLGG manuscripts on (1) pLGG preclinical models, (2) consensus framework for conducting early-phase clinical trials in pLGG, and (3) pLGG resistance, rebound, and recurrence. [Click here to read the full article.](#)



## 2023 SNO Annual Meeting Poster Winners

SNO would like to congratulate our 2023 Poster Award Winners!

- **Julio Sanchez** - PTEN loss in glioma cell lines facilitates immune evasion by upregulating extracellular vesicle biogenesis and PD-L1 cargo
- **Stefanie-Grace Sbergio** - Tumour-Targeted pan-RAS Inhibition as a Novel Therapy for Diffuse Intrinsic Pontine Glioma (DIPG)
- **Sebastian Waszak** - Rare and novel KIAA1549-BRAF fusion breakpoints predict poor clinical outcome for patients with recurrent or progressive pediatric low-grade glioma: phase II PNOC001 trial results.
- **Hirokazu Takami** - Phase II Trial of Pathology-based Three-group Treatment Stratification for Patients with CNS Germ Cell Tumors: A Long-term Follow-up Study
- **Brian Meehan** - Therapeutic window enabling eradication of residual glioma stem cells by intracranial NK cell and extracellular vesicle-mediated therapy following temozolomide-induced tumour depopulation
- **Darwin Kwok** - Public tumor-wide neoantigens derived from clonal aberrant splicing events drive tumor-specific T-cell responses
- **Levi van Hijfte** - Perivascular containment of T cells in IDH-mutant astrocytoma associates with high abundance of gemistocytic tumor cells and immune stimulatory microglia
- **Balagopal Pai** - Biology of glioblastoma invasion: a single-cell level analysis of tumor core vs. infiltrating edge
- **Kaylene Lu** - CARM1 is a novel tumor suppressor in glioblastoma that regulates Qki through arginine methylation
- **Defne Bayik** - g-aminobutyric acid drives glioblastoma in females by activating the complement system
- **Anahita Fathi Kazerooni** - Radioimmunomic Signatures in Pediatric Low-grade Glioma for Non-invasive Identification of Immunotherapeutic Targets

To view all of the scientific abstracts accepted for the 2023 SNO Annual Meeting, [click here.](#)



## This Week's Featured Listing

The OU Health Stephenson Cancer Center seeks a Medical Oncologist to join its academically driven team for a role spanning education, teaching, research, and patient care. This faculty medical oncology position has opportunities in various disease specialties, such as Breast, Urology, Malignant Hematology, Thoracic, Urologic Oncology, GI, Sarcoma, and Melanoma. [Click here to apply or see other postings!](#)


## Upcoming SNO and SNO Affiliated Events



### 2024 SNO/ASCO CNS Metastases Conference

[Abstract Submission Now Open!](#)

August 8-10, 2024  
Denver, Colorado



### 29<sup>th</sup> Annual Meeting and Education Day

Save The Date!  
November 21-24, 2024  
Houston, Texas



### 21<sup>st</sup> International Symposium on Pediatric Neuro-Oncology

[Abstract Submission Now Open!](#)

June 28 - July 2, 2024  
Philadelphia, PA

## Advertise in the SNO Digest

Are you looking for an effective way to reach an audience of 18,000 neuro-oncology professionals? Advertising in the SNO Digest weekly newsletter is the perfect way to get the word out about your business! [Click here](#) for more information.

### SNO Digest Co-Editors

- Iyad Alnahhas, MD, MSc
- Wenya Linda Bi, MD, PhD
- Nancy Wang, MD, MPH
- Holly Lindsay, MD, MS

### SNO Team Admin Support

- Shelley Pressley - Director of Administration
- Gabrielle Griffin - Marketing and Communications Specialist

### SNO Social Media Director

- Mustafa Khasraw, MD

## Connect With SNO on Social Media

Are you following us on our socials? We're constantly sharing updates on SNO events and

the latest news from the neuro-oncology field. Check us out on LinkedIn and Twitter.



*SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org).*

**Society for Neuro-Oncology** | [Website](#)  
[Subscribe to the SNO Digest](#)



Society for Neuro-Oncology | PO 273296, Houston, TX 77277

[Unsubscribe megan@soc-neuro-onc.org](mailto:megan@soc-neuro-onc.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org) powered by



Try email marketing for free today!